Novavax Inc SEC filings NVAX
Novavax Inc has 1,003 filings in SEC EDGAR's recent list, going back to Feb 14, 2013. Its latest annual report, Form ARS, was filed on Apr 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DFAN14A | Filing | May 20, 2024 | — |
| UPLOAD | Letter from the SEC | May 14, 2024 | — |
| DFAN14A | Filing | May 13, 2024 | — |
| DFAN14A | Filing | May 8, 2024 | — |
| DFAN14A | Filing | May 7, 2024 | — |
| DFAN14A | Filing | May 6, 2024 | — |
| PREC14A | Filing | May 6, 2024 | — |
| DEFR14A | Filing | May 3, 2023 | — |
| NT 10-Q | Filing | Nov 10, 2020 | Sep 30, 2020 |
| EFFECT | Filing | Jan 9, 2020 | — |
| CORRESP | Letter to the SEC | Jan 7, 2020 | — |
| UPLOAD | Letter from the SEC | Jan 6, 2020 | — |
| CT ORDER | Filing | Dec 17, 2018 | — |
| CT ORDER | Filing | Jun 12, 2018 | — |
| EFFECT | Filing | Jan 12, 2018 | — |
| CORRESP | Letter to the SEC | Jan 10, 2018 | — |
| UPLOAD | Letter from the SEC | Jan 9, 2018 | — |
| UPLOAD | Letter from the SEC | Dec 21, 2017 | — |
| CORRESP | Letter to the SEC | Dec 4, 2017 | — |
| UPLOAD | Letter from the SEC | Nov 30, 2017 | — |
| EFFECT | Filing | Jan 19, 2017 | — |
| CORRESP | Letter to the SEC | Jan 18, 2017 | — |
| UPLOAD | Letter from the SEC | Jan 12, 2017 | — |
| UPLOAD | Letter from the SEC | Jan 11, 2017 | — |
| CORRESP | Letter to the SEC | Dec 20, 2016 | — |
| UPLOAD | Letter from the SEC | Dec 6, 2016 | — |
| CT ORDER | Filing | Jan 8, 2016 | — |
| CT ORDER | Filing | Sep 25, 2015 | — |
| CT ORDER | Filing | Sep 22, 2015 | — |
| UPLOAD | Letter from the SEC | Apr 28, 2015 | — |
| CORRESP | Letter to the SEC | Apr 28, 2015 | — |
| UPLOAD | Letter from the SEC | Apr 24, 2015 | — |
| CT ORDER | Filing | Feb 3, 2015 | — |
| DEFR14A | Filing | May 7, 2014 | — |
| CT ORDER | Filing | Apr 14, 2014 | — |
| CT ORDER | Filing | Apr 14, 2014 | — |
| CB | Form cb | Jul 9, 2013 | — |
| EFFECT | Filing | Jul 8, 2013 | — |
| 425 | Current report | Jul 8, 2013 | — |
| 425 | Form 8-k | Jun 17, 2013 | — |
| 425 | Form 8-k | Jun 4, 2013 | — |
| EFFECT | Filing | May 2, 2013 | — |
| CORRESP | Letter to the SEC | Apr 30, 2013 | — |
| UPLOAD | Letter from the SEC | Mar 19, 2013 | — |
Showing 44 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- NVAX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Gaithersburg, MD
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1000694
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.